Treatments:Cancer
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
<td style="width:25%; vertical-align:top;border-width:1px;"> | <td style="width:25%; vertical-align:top;border-width:1px;"> | ||
=====Anti-CD20 [[Monoclonal Antibody]]===== | =====Anti-CD20 [[Monoclonal Antibody]]===== | ||
| - | * [[Arzerra]] - Generic: Ofatumumab | + | * [[Arzerra]] - Generic: [[Ofatumumab]] |
* [[Rituxan]] - Generic: Rituximab | * [[Rituxan]] - Generic: Rituximab | ||
=====Anti-melanoma [[Monoclonal Antibody]]===== | =====Anti-melanoma [[Monoclonal Antibody]]===== | ||
Revision as of 11:18, 23 January 2019
Anti-CD20 Monoclonal Antibody
Anti-melanoma Monoclonal Antibody
B-Raf Kinase Inhibitor
Chemotherapy
Dihydrofolate Reductase Inhibitor
Epidermal Growth Factor Receptor Inhibitor
Estrogen Receptor Modulator
Multiple Receptor Tyrosine Kinase (VEGFR, PDGFR, EGFR, KIT, Abl) Inhibitor
Vascular Endothelial Growth Factor Inhibitor
|
Proteopedia Page Contributors and Editors (what is this?)
David Canner, Michal Harel, Alexander Berchansky, Karsten Theis
